CL2019002511A1 - Composición farmacéutica que comprende selexipag. - Google Patents

Composición farmacéutica que comprende selexipag.

Info

Publication number
CL2019002511A1
CL2019002511A1 CL2019002511A CL2019002511A CL2019002511A1 CL 2019002511 A1 CL2019002511 A1 CL 2019002511A1 CL 2019002511 A CL2019002511 A CL 2019002511A CL 2019002511 A CL2019002511 A CL 2019002511A CL 2019002511 A1 CL2019002511 A1 CL 2019002511A1
Authority
CL
Chile
Prior art keywords
aqueous
compositions
pharmaceutical composition
selexipag
pharmaceutical compositions
Prior art date
Application number
CL2019002511A
Other languages
English (en)
Inventor
Klaus Hellerbrand
Alexandra Schlicker-Spain
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002511(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CL2019002511A1 publication Critical patent/CL2019002511A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCIÓN SE RELACIONA CON COMPOSICIONES FARMACÉUTICAS ACUOSAS QUE COMPRENDEN EL COMPUESTO 2-{4-[N-(5,6-DIFENILPIRAZIN-2-IL)-N-ISOPROPILAMINO]BUTILOXI}-N-(METILSULFONIL) ACETAMIDA; GLICINA; POLISORBATO 20; Y UN REGULADOR DE FOSFATO ACUOSO, EN DONDE LAS CANTIDADES RELATIVAS SON COMO SE DESCRIBIÓ EN LA DESCRIPCIÓN, EN DONDE EL PH DE DICHA COMPOSICIÓN FARMACÉUTICA ESTÁ ENTRE APROXIMADAMENTE 7 Y 8; CON COMPOSICIONES FARMACÉUTICAS LIOFILIZADAS PREPARADAS A PARTIR DE DICHAS COMPOSICIONES ACUOSAS, Y CON COMPOSICIONES ACUOSAS RECONSTITUIDAS DE ESTAS QUE SON ADECUADAS PARA ADMINISTRACIÓN I.V. LA INVENCIÓN SE RELACIONA, ADEMÁS, CON PROCESOS PARA LA PREPARACIÓN DE DICHAS COMPOSICIONES, Y CON SU USO PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON EL RECEPTOR IP.
CL2019002511A 2017-03-08 2019-09-02 Composición farmacéutica que comprende selexipag. CL2019002511A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08

Publications (1)

Publication Number Publication Date
CL2019002511A1 true CL2019002511A1 (es) 2020-01-17

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002511A CL2019002511A1 (es) 2017-03-08 2019-09-02 Composición farmacéutica que comprende selexipag.

Country Status (27)

Country Link
US (1) US20200129506A1 (es)
EP (1) EP3592391B1 (es)
JP (1) JP6964679B2 (es)
KR (1) KR102593075B1 (es)
CN (1) CN110430900B (es)
AR (1) AR111570A1 (es)
AU (1) AU2018229750B2 (es)
BR (1) BR112019018420A2 (es)
CA (1) CA3055010A1 (es)
CL (1) CL2019002511A1 (es)
CO (1) CO2019009221A2 (es)
CR (1) CR20190455A (es)
DO (1) DOP2019000250A (es)
EA (1) EA201992074A1 (es)
EC (1) ECSP19072294A (es)
ES (1) ES2880009T3 (es)
IL (1) IL269061A (es)
JO (1) JOP20190204A1 (es)
MA (1) MA47816A (es)
MX (1) MX2019010598A (es)
NI (1) NI201900090A (es)
PE (1) PE20191492A1 (es)
PH (1) PH12019502033A1 (es)
PL (1) PL3592391T3 (es)
SG (1) SG11201907804QA (es)
TW (1) TWI764996B (es)
WO (1) WO2018162527A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965767A1 (en) * 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Methods for treating sarcoidosis-associated pulmonary hypertension
WO2020249602A1 (en) * 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
CA3154802A1 (en) 2019-10-23 2021-04-29 Marc Patrik SCHRADER Pharmaceutical composition comprising selexipag
EP4096643A1 (en) 2020-01-31 2022-12-07 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022215045A1 (en) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Lyophilized composition comprising selexipag
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023209731A1 (en) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
TW202404594A (zh) * 2022-06-10 2024-02-01 日商日本新藥股份有限公司 醫藥組合物
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CA2476494C (en) * 2002-02-22 2010-04-27 Schering Corporation Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
BRPI0908491A2 (pt) 2008-02-28 2015-08-11 Nippon Shinyaku Co Ltd Inibidor de fibrose
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
SI2289518T1 (sl) 2008-06-23 2017-02-28 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za vnetno črevesno bolezen
WO2009157396A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US8791122B2 (en) * 2009-06-26 2014-07-29 Nippon Shinyaku Co., Ltd. Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
EP2699243A1 (en) * 2011-04-19 2014-02-26 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
JP2014522878A (ja) * 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス プロスタサイクリンの徐放組成物
EP2913047B1 (en) * 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
EP3043775B1 (en) * 2013-09-11 2020-11-04 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
GB201400412D0 (en) 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
EP3192502A1 (en) * 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag

Also Published As

Publication number Publication date
CN110430900A (zh) 2019-11-08
AR111570A1 (es) 2019-07-31
EP3592391A1 (en) 2020-01-15
TW201842910A (zh) 2018-12-16
BR112019018420A2 (pt) 2020-04-14
SG11201907804QA (en) 2019-09-27
IL269061A (en) 2019-11-28
CA3055010A1 (en) 2018-09-13
MA47816A (fr) 2020-01-15
JOP20190204A1 (ar) 2019-09-05
KR102593075B1 (ko) 2023-10-23
EA201992074A1 (ru) 2020-02-27
US20200129506A1 (en) 2020-04-30
ECSP19072294A (es) 2019-11-30
AU2018229750A1 (en) 2019-09-12
PL3592391T3 (pl) 2021-11-02
DOP2019000250A (es) 2020-09-15
JP6964679B2 (ja) 2021-11-10
WO2018162527A1 (en) 2018-09-13
PH12019502033A1 (en) 2020-06-15
CN110430900B (zh) 2023-09-19
JP2020509070A (ja) 2020-03-26
CO2019009221A2 (es) 2019-08-30
NI201900090A (es) 2020-03-11
PE20191492A1 (es) 2019-10-21
CR20190455A (es) 2019-11-12
TWI764996B (zh) 2022-05-21
AU2018229750B2 (en) 2023-11-23
EP3592391B1 (en) 2021-04-21
ES2880009T3 (es) 2021-11-23
MX2019010598A (es) 2019-10-15
KR20190122803A (ko) 2019-10-30

Similar Documents

Publication Publication Date Title
CL2019002511A1 (es) Composición farmacéutica que comprende selexipag.
EA202191559A1 (ru) Модифицированные аминовые липиды
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
EA202090890A1 (ru) Состав растительного и синтетического каннабиноида быстрого начала действия и пролонгированного действия
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA202090573A1 (ru) Составы нирапариба
BR112018013979A2 (pt) composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos
CL2022000998A1 (es) Inhibidores de las cinasas raf
UY37971A (es) Derivados de indol macrocíclicos sustituidos
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
MX2020009235A (es) Formulacion oftalmica.
CL2020002891A1 (es) Nuevos derivados de quinolina
CO6400235A2 (es) Tensiactivos reconstituidos que tienen propiedades mejoradas
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
BR112021025458A2 (pt) Formulação farmacêutica, método de preparação e uso da mesma
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112020004935A8 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
BR112017019431A2 (pt) material de implante de compósito
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
EA201892842A1 (ru) Фармацевтические композиции, включающие сафинамид